The Siemens Symbia VA10A Family is intended for use by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning or additional uses.

SPECT: The SPECT component is intended to detect or image the distribution of radionuclides in the body or organ (physiology), using the following techniques: planar imaging, whole body imaging, and tomographic imaging for isotopes with energies up to 588 keV.

CT: The CT component is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data (anatomy) from either the same axial plane taken at different angles or spiral planes taken at different angles.

SPECT+CT: The SPECT and CT components used together acquire SPECT/CT images. The SPECT images can be corrected for attenuation with the CT images, and can be combined (image registration) to merge the patient's physiological (SPECT) and anatomical (CT) images.

Software: The SPECTsyngo software is an acquisition, display and analysis package intended to aid the clinician in the assessment and quantification of pathologies in images produced from SPECT, PET, CT, and other imaging modalities.

This CT system can be used for low dose lung cancer screening in high risk populations *

*As defined by professional medical societies. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011; 365:395-409) and subsequent literature, for further information.

Device Description

The Siemens Symbia VA10A Family consists of Single-Photon Emission Computed Tomography (SPECT) scanner and integrated hybrid x-ray Computed Tomography (CT) and SPECT scanner.

The SPECT subsystem images and measures the distribution of radiopharmaceuticals in humans for the purpose of determining various metabolic (molecular) and physiologic functions within the human body and integrates CT's anatomical detail for precise reference of the location of the metabolic activity.

The CT component produces cross-sectional images of the body by computer reconstruction of x-ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles.

The system can be used as an integrated SPECT and CT modality while also enabling independent functionality of SPECT and CT as stand-alone diagnostic imaging devices.

Siemens Symbia VA10A Family maintains the same intended use and indications for use as the commercially available Intevo Bold System of Symbia 6.7 (K200474).

Symbia VA10A Family are hybrid modality imaging systems comprised of two separate but integrated components: a gamma camera (SPECT) and a CT. The gamma camera is based on hardware and software features that generate nuclear medicine images based on the uptake of radioisotope tracers in a patient's body. The CT system (spiral CT) is designed to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles.

The combination of SPECT and CT in a single device has several benefits. The SPECT subsystem images biochemical function while the CT subsystem images anatomy. The combination enables scans that not only indicate function, e.g., how active a tumor is, but precise localization, e.g., the precise location of that tumor in the body.

In addition, CT can be used to correct for the attenuation in SPECT acquisitions. Attenuation in SPECT is an unwanted side effect of the gamma rays scattering and being absorbed by tissue. This can lead to errors in the final image. The CT directly measures attenuation and can be used to create a 3D attenuation map of the patient which can be used to correct the SPECT images. The SPECT-CT scanner can be used to image and track how much dose was delivered to both the target and the surrounding tissue.

The systems consist of display equipment, data storage devices, patient and equipment supports and component parts and accessories.

Symbia VA10A update is the product name for the additional features to the approved Symbia VA10A Family (K210557). The Symbia VA10A Update devices are based on the Symbia VA10A Family. The difference lies in the additional features and update to the Indications for Use to include CT Low Dose Lung Screening (as cleared in reference device K200524). The Intended Purpose and fundamental scientific technology remain unchanged.

Proposed New Features for VA10A Family

SMARTZoom (SZHRX) Collimator
SMARTZoom Collimator
Plan&Go ●
TeamPlay ●
High Performance ICS ●
Automatic Quality Control
Expert-i
IQSPECT
xSPECT (including xSPECT Bone and xSPECT Quant) ●
BroadQuant
TrueCalc ●
Support for Third-Party Collimators
Specialty Pallets ●

AI/ML Overview

The provided document is a 510(k) summary for the Siemens Symbia VA10A Family, which is a SPECT/CT system. The document focuses on demonstrating substantial equivalence to predicate devices rather than proving performance against specific acceptance criteria through a standalone clinical study. The device is a diagnostic imaging system, not an AI-powered diagnostic device in the sense of providing automated interpretations or predictions.

Therefore, many of the requested elements for an AI device (like test set size, expert ground truth, adjudication methods, MRMC studies, training set size, etc.) are not applicable or not detailed in this type of submission. The performance testing described primarily relates to technical specifications of the imaging hardware and software, and compliance with regulatory standards.

Here's an attempt to extract the relevant information based on the provided text, while also noting where information is not available:

1. Table of Acceptance Criteria and Reported Device Performance

The document primarily focuses on demonstrating compliance with regulatory standards and maintaining performance specs of the predicate devices. Specific 'acceptance criteria' in terms of clinical performance metrics (e.g., sensitivity, specificity for a diagnostic task) are not explicitly stated or measured for this submission, as it's an update to an existing system. The performance tables provided are for the intrinsic detector specifications of the SPECT component, and the CT component's performance is stated to be unchanged from a predicate device and tested against regulatory standards.

Acceptance Criteria (Stated or Implied)	Reported Device Performance
SPECT Detector Specifications (NEMA NU-1)
Intrinsic spatial resolution - Tc99m FWHM in CFOV: ≤3.8 mm	≤3.8 mm (Meets criteria)
Intrinsic spatial resolution - Tc99m FWHM in UFOV: ≤3.9 mm	≤3.9 mm (Meets criteria)
Intrinsic spatial resolution - Tc99m FWTM in CFOV: ≤7.5 mm	≤7.5 mm (Meets criteria)
Intrinsic spatial resolution - Tc99m FWTM in UFOV: ≤7.7 mm	≤7.7 mm (Meets criteria)
Intrinsic spatial linearity - Tc99m Differential in CFOV: ≤0.2 mm	≤0.2 mm (Meets criteria)
Intrinsic spatial linearity - Tc99m Differential in UFOV: ≤0.2 mm	≤0.2 mm (Meets criteria)
Intrinsic spatial linearity - Tc99m Absolute in CFOV: ≤0.4 mm	≤0.4 mm (Meets criteria)
Intrinsic spatial linearity - Tc99m Absolute in UFOV: ≤0.7 mm	≤0.7 mm (Meets criteria)
Intrinsic energy resolution FWHM in CFOV: ≤9.9%	≤9.9% (Meets criteria)
Intrinsic flood field uniformity (uncorrected) - Tc99m Differential in CFOV: ≤2.5%	≤2.5% (Meets criteria)
Intrinsic flood field uniformity (uncorrected) - Tc99m Differential in UFOV: ≤2.7%	≤2.7% (Meets criteria)
Intrinsic flood field uniformity (uncorrected) - Tc99m Integral in CFOV: ≤2.9%	≤2.9% (Meets criteria)
Intrinsic flood field uniformity (uncorrected) - Tc99m Integral in UFOV: ≤3.7%	≤3.7% (Meets criteria)
CT Subsystem
Compliance with 21 CFR 1020.30, 21 CFR 1020.33, IEC 60601-2-44	Bench testing performed and met these standards (Unchanged from K200524)
Software Functional Performance
Functionality described in specifications are met	All planned test cases were executed and met functionality
Mitigations required by risk analysis are implemented	Mitigations implemented; residual risks reduced
Quality in planning documentation adhered to	Adhered to

2. Sample size used for the test set and the data provenance:

Test Set Sample Size: Not explicitly stated as this is a hardware/software update rather than a clinical performance study with patient data. The "test set" in this context refers to engineering and quality assurance testing of the system's technical aspects, not a clinical validation dataset.
Data Provenance: Not applicable. The performance testing is described as "Bench testing" and "Performance testing" conducted in accordance with NEMA and IEC standards. It doesn't involve clinical data in the sense of patient images for diagnostic performance evaluation in this specific submission.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

Not applicable/Not stated. The performance tests described (e.g., spatial resolution, energy resolution) are objective measurements using phantoms or calibrated instruments, not clinical interpretation by experts. For software verification and validation, "experts" would likely refer to internal engineers and testers.

4. Adjudication method for the test set:

Not applicable/Not stated. No clinical adjudication is described.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

No. This device is an imaging system (SPECT/CT scanner and associated processing software), not an AI-assisted diagnostic tool designed to directly improve human reader performance in interpreting images beyond providing the images themselves.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

Yes, in a sense. The "standalone" performance testing refers to the system's intrinsic technical performance (e.g., detector specifications, CT subsystem compliance) as measured against engineering standards. However, it's not a standalone diagnostic algorithm performance study. The SPECTsyngo software is an "acquisition, display and analysis package intended to aid the clinician," implying human-in-the-loop.

7. The type of ground truth used:

For hardware performance (SPECT detector, CT subsystem): Physical measurements, calibrated instruments, and established engineering standards (NEMA NU-1, IEC 60601 series, 21 CFR regulations).
For software: Functional specifications and requirements.

8. The sample size for the training set:

Not applicable/Not stated. This is not an AI algorithm that requires a "training set" of patient data in the machine learning sense. The "training" of the device refers to its design and development processes.

9. How the ground truth for the training set was established:

Not applicable.

Summary

{0}------------------------------------------------

September 16, 2021

Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym along with the full name of the agency on the right. The FDA acronym and the words "U.S. FOOD & DRUG" are in a blue sans-serif font, with "ADMINISTRATION" in a smaller font below.

Siemens Medical Solutions USA, Inc. % Tabitha Estes Regulatory Affairs Specialist 810 Innovation Drive KNOXVILLE TN 37932

Re: K212604

Trade/Device Name: Symbia VA10A Family Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: Class II Product Code: KPS, JAK Dated: August 14, 2021 Received: August 17, 2021

Dear Tabitha Estes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmp/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or post-marketing safety reporting (21 CFR 4, Subpart B) for combination products (see

{1}------------------------------------------------

https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known)

K212604

Device Name Symbia VA10A Family

Indications for Use (Describe)

SPECT: The SPECT component is intended to detect or mage the distribution of radionuclides in the body or organ (physiology), using the following techniques: planar imaging, and tomographic imaging for isotopes with energies up to 588 keV.

SPECT+CT: The SPECT and CT components used together acquire SPECT/CT images can be corrected for attenuation with the CT images, and can be combined (image registration) to merge the patient's physiological (SPECT) and anatomical (CT) images.

This CT system can be used for low dose lung cancer screening in high-risk populations * *As defined by professional medical societies. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011; 365:395-409) and subsequent literature, for further information.

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

as required by 21 CFR Part 807.87(h)

Identification of the Submitter

Submitter:	Tabitha EstesRegulatory Affairs SpecialistSiemens Molecular Solutions USA, Inc.810 Innovation DriveKnoxville, TN 37932
Manufacturer:	Siemens Medical Solutions USA, Inc.Molecular Imaging2501 North Barrington RoadHoffman Estates, IL 60192
Telephone Number:	(865) 804 - 4553
Date of Submission:	August 14th, 2021

Identification of the product

Device Proprietary Name:	Symbia VA10A Family
Common Name:	Single-Photon Emission Computed Tomography (SPECT)SystemComputed Tomography (CT) System
Classification Name:	Emission Computed Tomography System per 21 CFR892.1200Computed Tomography X-Ray System per 21 CFR892.1750
Product Code:	KPS and JAK
Classification Panel:	Radiology
Device Class:	Class II
Device Proprietary Name:	Symbia VA10A Family
Common Name:	Single-Photon Emission Computed Tomography (SPECT)SystemComputed Tomography (CT System
Classification Name:	Emission Computed Tomography System per 21 CFR892.1200Computed Tomography X-Ray System per 21 CFR892.1750
Manufacturer:	Siemens Medical Solutions USA, Inc.
Product Code:	KPS and JAK
Classification Panel:	Radiology
Device Class:	Class II
510(k) Number:	K210557
Reference Device:
Device Name and 510(k)numbers:	Scan&GO, SOMATOM Go.Platform
Common Name:	Computed Tomography X-Ray System
Classification Name:	Computed Tomography X-Ray System per 21 CFR892.1750Picture Archiving and Communications System per 21 CFR892.2050
Manufacturer:	Siemens Healthcare GmbH
Product Code:	LLZ, JAK
Classification Panel:	Radiology
Device Class:	Class II
510(k) Number:	K200524
Reference Device:
Device Name and 510(k)numbers:	Symbia Intevo Bold
Common Name:	Single-Photon Emission Computed Tomography (SPECT)SystemComputed Tomography (CT) System
Classification Name:	Emission Computed Tomography System per 21 CFR892.1200Computed Tomography X-Ray System per 21 CFR892.1750
Manufacturer:	Siemens Medical Solutions USA, Inc.
Product Code:	KPS and JAK
Classification Panel:	Radiology
Device Class:	Class II
510(k) Number:	K200474
Reference Device:
Device Name and 510(k)numbers:	MI View&Go VA10A
Common Name:	Image Processing Software
Classification Name:	Picture Archiving and Communications System per 21 CFR892.2050
Manufacturer:	Siemens Medical Solution, USA, Inc.
Product Code:	LLZ
Classification Panel:	Radiology
Device Class:	Class II
510(k) Number:	K201202

{4}------------------------------------------------

Marketed Devices to which Equivalence is claimed:

Predicate Device:

{5}------------------------------------------------

{6}------------------------------------------------

Device Description:

The Siemens Symbia VA10A Family consists of Single-Photon Emission Computed Tomography (SPECT) scanner and integrated hybrid x-ray Computed Tomography (CT) and SPECT scanner.

The system can be used as an integrated SPECT and CT modality while also enabling independent functionality of SPECT and CT as stand-alone diagnostic imaging devices.

Siemens Symbia VA10A Family maintains the same intended use and indications for use as the commercially available Intevo Bold System of Symbia 6.7 (K200474).

{7}------------------------------------------------

The systems consist of display equipment, data storage devices, patient and equipment supports and component parts and accessories.

Proposed New Features for VA10A Family

SMARTZoom (SZHRX) Collimator
SMARTZoom Collimator
Plan&Go ●
TeamPlay ●
High Performance ICS ●
Automatic Quality Control
Expert-i
IQSPECT
xSPECT (including xSPECT Bone and xSPECT Quant) ●
BroadQuant
TrueCalc ●
Support for Third-Party Collimators
Specialty Pallets ●

Intended Use:

The Symbia VA10A Family device is a radiological imaging system that combines a single photon emission computed tomography (SPECT) camera system for nuclear medicine images, and a computed tomography (CT) camera system for x-ray images.

The SPECT system is intended to detect the location and distribution of gamma ray radionuclides in the body and produce cross-sectional images through computer reconstruction of the data, and the CT system is intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. The nuclear medicine images and the x-ray images may be registered and displayed in a fused format (overlaid in the same orientation) for the anatomical localization of the nuclear medicine data (that is, distribution of radiopharmaceuticals). The SPECT and CT portions of the system may be used independently or in combination, and may include signal analysis and display equipment, patient and equipment support, radionuclide anatomical markers, component parts, and accessories. The SPECT and CT images may be transferred to other systems for radiation therapy planning or additional uses.

{8}------------------------------------------------

Indications for Use:

This CT system can be used for low dose lung cancer screening in high risk populations *

There are no known contraindications.

Technological Characteristics:

Performance Testing:

Performance testing for the CT subsystem was included in the original premarket notification for the CT subsystems (K200524) and there have been no changes affecting this testing.

Each CT subsystem is tested and passes the Applicable Performance

Standards prior to shipment:

· 21 CFR 1020.30 (a) Applicability
· 21 CFR 1020.30 (b)(36)(iii)-(v) Technique Factors

{9}------------------------------------------------

· 21 CFR 1020.30 (b)(58)-(62) CT, Scan, Scan Time, Tomogram, Dose
· 21 CFR 1020.30 (h)(3)(vi)-(viii) Information to be provided for users
· 21 CFR 1020.33 Computed Tomography (CT) equipment
・21 CFR 1040.10 Laser Products
· 21 CFR 1040.11 Specific purpose laser products

Symbia VA10A Family systems are designed in accordance with the 60601-1 series including all relevant collateral standards general (IEC 60601-1, 1-2, 1-3, etc.) and specific (IEC 60601-2-44). Performance testing is conducted according to NEMA NU-1. All Performance testing met the predetermined acceptance values.

Detector Specifications
Intrinsic spatial resolution - Tc99m	SPECT	3/8"
FWHM in CFOV	SPECT	≤3.8 mm
FWHM in UFOV	SPECT	≤3.9 mm
FWTM in CFOV	SPECT	≤7.5 mm
FWTM in UFOV	SPECT	≤7.7 mm
Intrinsic spatial linearity - Tc99m	SPECT
Differential in CFOV	SPECT	≤0.2 mm
Differential in UFOV	SPECT	≤0.2 mm
Absolute in CFOV	SPECT	≤0.4 mm
Absolute in UFOV	SPECT	≤0.7 mm
Intrinsic energy resolution	SPECT
FWHM in CFOV	SPECT	≤9.9%
Intrinsic flood field uniformity (uncorrected) -Tc99m	SPECT
Differential in CFOV	SPECT	≤2.5%
Differential in UFOV	SPECT	≤2.7%
Integral in CFOV	SPECT	≤2.9%
Integral in UFOV	SPECT	≤3.7%

Existing NEMA detector and collimator performance specifications do not change between the commercially available Symbia VA10A Family and proposed Symbia VA10A Update systems.

{10}------------------------------------------------

There are no changes in the system design that could impact the SPECT performance specifications and the commercially available specifications still apply.

Bench testing performed on the CT subsystem is conducted in accordance with IEC 60601-2-44 and in accordance with US regulations including 21 CFR 1020.33, Computed Tomography (CT) equipment. This is unchanged from the commercially available SOMATOM go CT systems (K200524).

Risk analyses performed at Siemens Medical Solutions USA; Inc. are in compliance with the requirements of:

IEC/ISO 14971 Medical Devices Application of Risk Management to Medical Devices ●
IEC 62304 Medical Device Software Software Life-cycle Processes 0

There is no significant difference in the risks imposed by this system and the risks associated with the predicate devices. The product Risk Management Team has reviewed and verified that all risks identified in the Symbia VA10A Product Risk Analysis has been adequately mitigated and the individual and overall residual risks are reduced as far as possible.

Verification and validation of Siemens software is performed in accordance with documented procedures, test plans and specifications. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software verification, and system testing.

System and System Integration testing (validation) was carried out for all features of the project, and all planned test cases were executed.

Verification and Validation is performed to:

ensure the functionality described in the specifications are met, 0
ensure the quality in the planning documentation is adhered to,
ensure mitigations required by risk analysis are implemented, and appropriate
identify additional issues that may be related to patient / operator safety, or effectiveness
assure that the specifications are appropriate to fulfill the intended use of the system. ●

Safety and Effectiveness:

The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of the device.

Risk Management is ensured via a risk analysis in compliance with ISO 14971 to identify and provide mitigation to potential hazards beginning early in the design cycle and continuing throughout the development of the product.

{11}------------------------------------------------

Cybersecurity information in accordance with FDA Guidance documents issued on October 2, 2014, has been provided. The Symbia VA10A Family systems software has specific cybersecurity controls to prevent unauthorized access, modifications, misuse or denial of use.

Additionally, controls are enabled to prevent the unauthorized use of information that is stored, accessed or transferred between the Symbia VA10A family systems and external devices.

Siemens Medical Solutions, USA Inc. adheres to recognized and established industry standards such as IEC 60601-1 series and 21 CFR 1020.30 and 21 CFR 1020.33 to minimize electrical, mechanical and radiation hazards.

Symbia VA10A Family conforms to applicable FDA recognized and international IEC, ISO and NEMA standards with regards to performance and safety as required by the respective SPECT FDA Guidance Documents. SPECT detector and CT performance is conducted according to NEMA NU1, and the performance does not change from the predicate device.

Verification and validation of Siemens systems is performed in accordance with documented procedures, design and code reviews, test plans and specifications. Traceability of the requirements specified in the requirement specifications and functional specifications is ensured during component integration, software validation and system testing.

Statement regarding Substantial Equivalence:

Symbia VA10A Update systems are based on the commercially available Symbia VA10A Family and have the same indications for use as well as utilizes the same fundamental scientific technology as the predicate device. The software updates pose no new issues of safety and / or efficacy. Siemens considers the Symbia VA10A Update to be as safe and effective as the commercially available predicate device with substantially equivalent performance.

Regulation Number and Section

§ 892.1200 Emission computed tomography system.

(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.